The Three In-frame ATG, Clustered in the Translation Initiation Sequence of Human Factor IX Gene, Are Required for an Optimal Protein Production

Summary

Three in-frame potential methionine codons have been identified in human factor IX gene and are clustered at amino acids -46, -41 and -39. In view of initiating a gene therapy approach, human factor IX production has been evaluated after modifications of these first three in-frame translation start sites. To characterize the most efficient translation initiation context, five factor IX cDNA expression vectors directed by CMV promoter-enhancer were generated. These vectors contained different starting site combinations including one, two or three ATG. A quantitative analysis of factor IX production in stably transfected CHO cells and in a rabbit reticulocyte lysate cell free system revealed the ability of all single site to generate fully active factor IX. However, the factor IX production level increased with the ATG number and the wild type (WT) cDNA bearing the 3 ATG induced the highest protein production. A truncated intron I of factor IX, previously suggested of having an expression-augmenting activity, was also placed in the WT factor IX cDNA. In stably transfected CHO cells, a 8-fold increase in protein production was measured. These results show that at least in vitro, the presence of the three ATG seems to be crucial for a maximal factor IX production. The data also suggest that both the three ATG and the truncated intron I are required for an optimal factor IX production in a perspective of a human gene therapy of haemophilia.

Keywords

Factor IX - translational initiation - CHO cells - factor IX production - factor IX intron I

¹ *: Both authors contributed equally to this work

• References

• 1 Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci 1977; 74: 5260-4.
• 2 Hedner U, Davie EW. Introduction to Hemostasis and Vitamin K-dependent Coagulation Factors. In: The Metabolic Basis of Inherited Diseases. 6. Sciver CR, Beaudet AL, Sly WS, Valle D. (eds) New York: McGraw Hill; 1989: 2107-34.
• 3 Choo KH, Gould KG, Rees DJ, Brownlee GG. Molecular cloning of the gene for human anti-haemophilic factor IX. Nature 1982; 29: 178-80.
• 4 Camerino G, Grzeschik KH, Jaye M, de La Salle H, Tolstoshev P, Lecocq JP, Heilig R, Mandel JL. Regional localization on the human X chromosome and polymorphism of the coagulation factor IX gene (hemophilia B locus). Proc Natl Acad Sci USA 1984; 81: 498-502.
• 5 Boyd Y, Buckle VJ, Munro EA, Choo KH, Migeon BR, Craig IW. Assignment of the haemophilia B (factor IX) locus to the q26-qter region of the X chromosome. Ann Hum Genet 1984; 48: 145-52.
• 6 Anson DS, Choo KH, Rees DJG, Giannelli F, Gould JA, Huddleston JA, Brownlee GG. The gene structure of human anti-haemophilic factor IX. EMBO J 1984; 3: 1053-60.
• 7 Yoshitake S, Schach B, Foster DC, Davie EW, Kurachi K. Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). Biochemistry 1985; 24: 3736-50.
• 8 Salier J-P, Hirosawa S, Kurachi K. Functional characterization of the 5’-regulatory region of human factor IX gene. J Biol Chem 1990; 265: 7062-8.
• 9 Reijnen MJ, Bertina RM, Reistma PH. Localization of the transcription initiation sites in the human coagulation factor IX gene. FEBS Lett 1990; 270: 207-10.
• 10 Kurachi S, Furukawa M, Salier JP, Wu CT, Wilson EJ, French FS, Kurachi K. Regulatory mechanism of human factor IX gene: protein binding at the Leiden specific region. Biochemistry 1994; 33: 1580-91.
• 11 Salier J-P, Kurachi S, Kurachi K. Haemophilia B Leiden: natural rescues of a transient deficiency in transcription. Médecine Sciences 1994; 10: 186-94.
• 12 Hirosawa S, Fahner JB, Salier J-P, Wu CT, Lovrien EW, Kurachi K. Structural and functional basis of the developmental regulation of human coagulation factor IX gene: factor IX Leiden. Proc Natl Acad Sci USA 1990; 87: 4421-5.
• 13 Giannelli F, Green PM, Sommer SS, Poon M, Ludwig M, Schwaab R, Reitsma PH, Haemophilia B. database of point mutations and short additions and deletions-eighth edition. Nucleic Acids Res 1998; 26: 265-8.
• 14 Reijnen MJ, Sladek FM, Bertina RM, Reistma PH. Disruption of a binding site for hepatocyte nuclear factor 4 results in hemophilia B Leiden. Proc Natl Acad Sci 1992; 89: 6300-3.
• 15 Crossley M, Brownlee GG. Disruption of a C/EBP binding site in the factor IX promoter is associated with haemophilia B. Nature 1990; 345: 444-6.
• 16 Boland EJ, Liu YC, Walter CA, Herbert DC, Weaker FJ, Odom MW, Jagadeeswaran P. Age-specific regulation of clotting factor IX gene expression in normal and transgenic mice. Blood 1995; 86: 2198-205.
• 17 Naka H, Brownlee GG. Transcriptional regulation of the human factor IX promoter by the orphan receptor superfamily factors, HNF4, ARP1 and COUP/Ear3. Br J Haematol 1996; 92: 231-40.
• 18 Pang CP, Crossley M, Kent G, Brownlee GG. Comparative sequence analysis of mammalian factor IX promoters. Nucleic Acids Res 1990; 18: 6731-2.
• 19 Roberts HR. Molecular biology of haemophilia B. Thromb Haemost 1993; 70: 1-9.
• 20 Pelletier J, Sonenberg N. Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature 1988; 334: 320-5.
• 21 Ossipow V, Descombes P, Schibler U. CCAAT/enhancer-binding protein mRNA is translated into multiple proteins with different transcription activation potentials. Proc Natl Acad Sci 1993; 90: 8219-23.
• 22 Kozak M. An analysis of vertebrate mRNA sequences: intimations of translational control. J Cell Biol 1991; 115: 887-903.
• 23 Kozak M. Interpreting cDNA sequences: some insights from studies on translation. Mamm Genome 1996; 7: 563-74.
• 24 Kozak M. At least six nucleotides preceeding the AUG initiator codon enhance translation in mammalian cells. J Mol Biol 1987; 196: 947-50.
• 25 Kurachi S, Hitomi Y, Furukawa M, Kurachi K. Role of the intron I in the expression of the human factor IX gene. J Biol Chem 1995; 270: 5276-81.
• 26 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
• 27 Sambrook J, Fritsh EF, Maniatis T. Molecular cloning; a laboratory manuel. Nolan C. (ed) New York: Cold Springer Laboratory Press; 1989
• 28 Lynch CM, Israel DI, Kaufman RJ, Miller D. Sequences in the coding of clotting factor VIII act as dominant inhibitors of RNA accumulation and protein production. Hum Gene Ther 1993; 4: 259-72.
• 29 Wakiyama M, Hirao I, Kumagai I, Miura K. Effect of tandem repeated AUG codons on translation efficiency of eukaryotic mRNA carrying a short leader sequence. Mol Gen Genet 1993; 23: 59-64.
• 30 Jackson RJ. A comparative view of initiation site selection mechanism. In: Translational Control. Hershley JWB, Mathews MB, Sonenberg N. (eds) New York: Cold Spring Harbor Laboratory press; 1996: 451-80.
• 31 Lu Z, Hanson K, DeLuca HF. Cloning origin of the two forms of chicken vitamin D receptor. Arch Biochem Biophys 1997; 339: 99-106.
• 32 Jallat S, Perraud F, Dalemans W, Balland A, Dieterle A, Faure T, Meulien P, Pavirani A. Characterization of recombinant human factor IX expressed in transgenic mice and in derived trans-immortalized hepatic cells. EMBO J 1990; 9: 3295-301.
• 33 Zheng B, Qiu XY, Tan M, Xing YN, Xue JL, Qiu XF. Increment of hFIX expression with endogenous intron I in vitro. Cell Res 1997; 7: 21-9.
• 34 Wang JM, Zheng H, Blaivas M, Kurachi K. Persistent systemic production of human factor IX in mice by skeletal myoblast-mediated gene transfer: feasibility of repeat application to obtain therapeutic levels. Blood 1997; 90: 1075-82.
• 35 Nakai H, Herzog RW, Hagstrom JN, Walter J, Kung SH, Yang EY, Tai SJ, Iwaki Y, Kurtzman GJ, Fisher KJ, Colosi P, Couto LB, High KA. Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. Blood 1998; 91: 4600-7.
• 36 Wang JM, Zheng H, Sugahara Y, Tan J, Yao SN, Olson E, Kurachi K. Construction of human factor IX expression vectors in retroviral vector frames optimized for muscle cells. Hum Gene Ther 1996; 7: 1743-56.